UnitedHealth Group raised its 2026 profit forecast on Tuesday, citing tighter control of medical spending and stronger margins in its clinical care business. It now expects adjusted earnings of at least $20.50 per share this year, up from its previous range of at least $19.50 to $20. Analysts had forecast $19.86, according to LSEG data.
That’s a striking reversal for a company that spent the past two years trying to turn itself around.
The Numbers
Third-quarter adjusted earnings reached $4.69 per share, up from $2.92 a year earlier and above the average analyst estimate of $4.14. Revenue hit $112.69 billion, topping Wall Street’s expectation of about $111.4 billion. Operating income rose to $6.6 billion from $4.3 billion in the year-ago quarter. Shares gained 2.1% to $386.61 in early trading.
The medical cost ratio, which measures the share of premiums spent on care, dropped to 88.4% from 89.90% a year earlier. That beat analyst estimates. UnitedHealth credited plan design and new product pricing, and recorded a $610 million reserve benefit tied to lower-than-expected claims for services provided earlier this year.
Mizuho analyst Ann Hynes said the quarter was solid, but “the real highlight was the continued durability of the margin recovery story.”
How the Company Got Here
The recovery didn’t come from growth. It came from cutting back. UnitedHealth exited some health insurance products this year and appointed new top executives after missing financial estimates last year. Optum, its clinical unit, dropped less favorable contracts for certain health plans that had hurt first-quarter earnings. The company said investments in technology, including artificial intelligence, lowered the overall cost of delivering medical services.
The cost of shrinking shows up in the membership data. Revenue from UnitedHealthcare, the insurance arm, fell to $86.3 billion from $87.1 billion a year earlier. Employer-sponsored plan membership declined by 165,000 people through attrition, while eligibility changes pushed another 85,000 people off Medicaid rolls. Since the end of 2025, 935,000 members have left its Medicare Advantage business. Even so, earnings from operations and profit margins climbed. The company credited benefit changes, pricing, and controls on medical and operating costs.
UnitedHealthcare runs Medicare Advantage plans for adults 65 and older, along with Medicaid plans for low-income Americans on behalf of state governments. In both programs, the government sets the rules and private insurers carry the risk.
Looking Ahead to 2027
Chief Financial Officer Wayne Deveydt told investors UnitedHealth is aiming for the lower end of its long-term growth-rate projection of 13% to 16% for 2027, calling it a “reasonable starting point.” He also said that “current analyst consensus for 2027 may understate the opportunity ahead.” Wall Street currently expects 2027 earnings of $22.61 per share.
The backdrop remains sobering. UnitedHealth operates one of the largest U.S. health insurers, alongside clinical care businesses, pharmacy services, and a pharmacy benefits manager. The company has faced one of the industry’s biggest cyber attacks, missed financial targets, and withdrawn its outlook under pressure. Nearly two years ago, the killing of a top executive outside its investor meeting in New York shook the company. Last year, UnitedHealth said Optum faced regulatory and cost challenges amounting to an $11 billion blow to the unit over three years.
Why This Matters:
UnitedHealth’s rebound shows what disciplined management can accomplish when a company sheds unprofitable business instead of chasing volume. Dropping money-losing products and contracts restored margins without a bailout or rescue. That’s the market doing its job. Yet the figures come with a warning. With 935,000 Medicare Advantage members gone since the end of 2025 and Medicaid rolls falling because of eligibility changes, some of the profit recovery reflects who’s no longer covered. Insurers reliant on government-run programs remain exposed to policy changes they can’t control. Investors and retirees watching their portfolios will want to know whether these margin gains last. For policymakers, it’s a reminder that pricing discipline, not mandates, steadies a major insurer.